Login Register Cart 0
Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Comprehensive Genomic Analysis of Puerarin in Inhibiting Bladder Urothelial Carcinoma Cell Proliferation and Migration

Author(s): Yu-yang Ma, Ge-jin Zhang, Peng-fei Liu, Ying Liu, Ji-cun Ding, Hao Xu, Lin Hao, Deng Pan, Hai-luo Wang, Jing-kai Wang, Peng Xu, Zhen-Duo Shi* and Kun Pang*

Volume 19, Issue 4, 2024

Published on: 28 September, 2023

Page: [516 - 529] Pages: 14

DOI: 10.2174/1574892819666230908110107

Price: $65

Abstract

Background: Bladder urothelial carcinoma (BUC) ranks second in the incidence of urogenital system tumors, and the treatment of BUC needs to be improved. Puerarin, a traditional Chinese medicine (TCM), has been shown to have various effects such as anti-cancer effects, the promotion of angiogenesis, and anti-inflammation. This study investigates the effects of puerarin on BUC and its molecular mechanisms.

Methods: Through GeneChip experiments, we obtained differentially expressed genes (DEGs) and analyzed these DEGs using the Ingenuity® Pathway Analysis (IPA®), Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) pathway enrichment analyses. The Cell Counting Kit 8 (CCK8) assay was used to verify the inhibitory effect of puerarin on the proliferation of BUC T24 cells. String combined with Cytoscape® was used to create the Protein-Protein Interaction (PPI) network, and the MCC algorithm in cytoHubba plugin was used to screen key genes. Gene Set Enrichment Analysis (GSEA®) was used to verify the correlation between key genes and cell proliferation.

Results: A total of 1617 DEGs were obtained by GeneChip. Based on the DEGs, the IPA® and pathway enrichment analysis showed they were mainly enriched in cancer cell proliferation and migration. CCK8 experiments proved that puerarin inhibited the proliferation of BUC T24 cells, and its IC50 at 48 hours was 218μmol/L. Through PPI and related algorithms, 7 key genes were obtained: ITGA1, LAMA3, LAMB3, LAMA4, PAK2, DMD, and UTRN. GSEA showed that these key genes were highly correlated with BUC cell proliferation. Survival curves showed that ITGA1 upregulation was associated with poor prognosis of BUC patients.

Conclusion: Our findings support the potential antitumor activity of puerarin in BUC. To the best of our knowledge, bioinformatics investigation suggests that puerarin demonstrates anticancer mechanisms via the upregulation of ITGA1, LAMA3 and 4, LAMB3, PAK2, DMD, and UTRN, all of which are involved in the proliferation and migration of bladder urothelial cancer cells.

« Previous Next »
[1]
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 2021; 71(1): 7-33.
[http://dx.doi.org/10.3322/caac.21654] [PMID: 33433946]
[2]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[3]
Jain P, Kathuria H, Momin M. Clinical therapies and nano drug delivery systems for urinary bladder cancer. Pharmacol Ther 2021; 226107871.
[http://dx.doi.org/10.1016/j.pharmthera.2021.107871] [PMID: 33915179]
[4]
Patel VG, Oh WK, Galsky MD. Treatment of muscle‐invasive and advanced bladder cancer in 2020. CA Cancer J Clin 2020; 70(5): 404-23.
[http://dx.doi.org/10.3322/caac.21631] [PMID: 32767764]
[5]
SUN D. Inventor method of treating cancer with composition of traditional chinese medicine and its preparation method thereof. Patent US2022133762, 2022.
[6]
Li X, Xu X, Wang Y. Inventors traditional chinese medicine composition for treating breast cancer and preparation method thereof. Patent AU2021101967A4, 2021.
[7]
Vitelli Storelli F, Molina AJ, Zamora-Ros R, et al. Flavonoids and the risk of gastric cancer: An exploratory case-control study in the MCC-spain study. Nutrients 2019; 11(5): 967.
[http://dx.doi.org/10.3390/nu11050967] [PMID: 31035601]
[8]
Xie Z, Wei Y, Xu J, Lei J, Yu J. Alkaloids from Piper nigrum synergistically enhanced the effect of paclitaxel against paclitaxel-resistant cervical cancer cells through the downregulation of Mcl-1. J Agric Food Chem 2019; 67(18): 5159-68.
[http://dx.doi.org/10.1021/acs.jafc.9b01320] [PMID: 31006247]
[9]
Zhang M, Zhang Y, Zhang L, Tian Q. Mushroom polysaccharide lentinan for treating different types of cancers: A review of 12 years clinical studies in China. Prog Mol Biol Transl Sci 2019; 163: 297-328.
[http://dx.doi.org/10.1016/bs.pmbts.2019.02.013] [PMID: 31030752]
[10]
Liao YH, Li CI, Lin CC, Lin JG, Chiang JH, Li TC. Traditional Chinese medicine as adjunctive therapy improves the long-term survival of lung cancer patients. J Cancer Res Clin Oncol 2017; 143(12): 2425-35.
[http://dx.doi.org/10.1007/s00432-017-2491-6] [PMID: 28803328]
[11]
Liu Y, Yang S, Wang K, et al. Cellular senescence and cancer: Focusing on traditional Chinese medicine and natural products. Cell Prolif 2020; 53(10): e12894.
[http://dx.doi.org/10.1111/cpr.12894] [PMID: 32881115]
[12]
Ma X, Yan L, Zhu Q, Shao F. Puerarin attenuates cisplatin-induced rat nephrotoxicity: The involvement of TLR4/NF-κB signaling pathway. PLoS One 2017; 12(2): e0171612.
[http://dx.doi.org/10.1371/journal.pone.0171612] [PMID: 28182789]
[13]
Liu X, Li S, Li Y, Cheng B, Tan B, Wang G. Puerarin inhibits proliferation and induces apoptosis by upregulation of miR-16 in bladder cancer cell line T24. Oncol Res 2018; 26(8): 1227-34.
[http://dx.doi.org/10.3727/096504018X15178736525106] [PMID: 29422113]
[14]
Xu H, Hu M, Liu M, et al. Nano-puerarin regulates tumor microenvironment and facilitates chemo- and immunotherapy in murine triple negative breast cancer model. Biomaterials 2020; 235119769.
[http://dx.doi.org/10.1016/j.biomaterials.2020.119769] [PMID: 31986348]
[15]
Jiang K, Chen H, Tang K, et al. Puerarin inhibits bladder cancer cell proliferation through the mTOR/p70S6K signaling pathway. Oncol Lett 2018; 15(1): 167-74.
[PMID: 29375709]
[16]
Du L, Zhang L, Sun F. Puerarin inhibits the progression of bladder cancer by regulating circ_0020394/miR-328-3p/NRBP1 Axis. Cancer Biother Radiopharm 2022; 37(6): 435-50.
[http://dx.doi.org/10.1089/cbr.2019.3382] [PMID: 33016781]
[17]
Ye G, Kan S, Chen J, Lu X. Puerarin in inducing apoptosis of bladder cancer cells through inhibiting SIRT1/p53 pathway. Oncol Lett 2019; 17(1): 195-200.
[PMID: 30655755]
[18]
Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun 2019; 10(1): 1523.
[http://dx.doi.org/10.1038/s41467-019-09234-6] [PMID: 30944313]
[19]
Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: Protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 2019; 47(D1): D607-13.
[http://dx.doi.org/10.1093/nar/gky1131] [PMID: 30476243]
[20]
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 2017; 45(W1): W98-W102.
[http://dx.doi.org/10.1093/nar/gkx247] [PMID: 28407145]
[21]
Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci 2005; 102(43): 15545-50.
[http://dx.doi.org/10.1073/pnas.0506580102] [PMID: 16199517]
[22]
Khan MI. Dębski KJ, Dabrowski M, Czarnecka AM, Szczylik C. Gene set enrichment analysis and ingenuity pathway analysis of metastatic clear cell renal cell carcinoma cell line. Am J Physiol Renal Physiol 2016; 311(2): F424-36.
[http://dx.doi.org/10.1152/ajprenal.00138.2016] [PMID: 27279483]
[23]
Li H, Wang Y, Rong S, et al. Integrin α1 promotes tumorigenicity and progressive capacity of colorectal cancer. Int J Biol Sci 2020; 16(5): 815-26.
[http://dx.doi.org/10.7150/ijbs.37275] [PMID: 32071551]
[24]
Zheng QH, Li XL, Mei ZG, et al. Efficacy and safety of puerarin injection in curing acute ischemic stroke: A meta-analysis of randomized controlled trials. Medicine (Baltimore) 2017 Jan; 96(1): 5803.
[http://dx.doi.org/10.1097/MD.0000000000005803] [PMID: 28072733]
[25]
Liu B, Tan Y, Wang D, et al. Puerarin for ischaemic stroke. Cochrane Database Syst Rev 2016 Feb 18; 2: CD004955.
[http://dx.doi.org/10.1002/14651858.CD004955.pub3] [PMID: 26891451]
[26]
Cai H, Kondo M, Sandhow L, et al. Critical role of Lama4 for hematopoiesis regeneration and acute myeloid leukemia progression. Blood 2022; 139(20): 3040-57.
[http://dx.doi.org/10.1182/blood.2021011510] [PMID: 34958665]
[27]
Zheng B, Qu J, Ohuchida K, et al. LAMA4 upregulation is associated with high liver metastasis potential and poor survival outcome of Pancreatic Cancer. Theranostics 2020; 10(22): 10274-89.
[http://dx.doi.org/10.7150/thno.47001] [PMID: 32929348]
[28]
Wang M, Li C, Liu Y, Wang Z. Effect of LAMA4 on prognosis and its correlation with immune infiltration in gastric cancer. BioMed Res Int 2021; 2021: 1-13.
[http://dx.doi.org/10.1155/2021/6428873] [PMID: 34414238]
[29]
Li Y, Guan B, Liu J, et al. MicroRNA-200b is downregulated and suppresses metastasis by targeting LAMA4 in renal cell carcinoma. EBioMedicine 2019; 44: 439-51.
[http://dx.doi.org/10.1016/j.ebiom.2019.05.041] [PMID: 31130475]
[30]
Liu Y, Xu Y, Ding L, Yu L, Zhang B, Wei D. LncRNA MEG3 suppressed the progression of ovarian cancer via sponging miR-30e-3p and regulating LAMA4 expression. Cancer Cell Int 2020; 20(1): 181.
[http://dx.doi.org/10.1186/s12935-020-01259-y] [PMID: 32489317]
[31]
Deng WW, Wu L, Bu LL, et al. PAK2 promotes migration and proliferation of salivary gland adenoid cystic carcinoma. Am J Transl Res 2016; 8(8): 3387-97.
[PMID: 27648129]
[32]
Zhu Z, Song J, Guo Y, et al. LAMB3 promotes tumour progression through the AKT–FOXO3/4 axis and is transcriptionally regulated by the BRD2/acetylated ELK4 complex in colorectal cancer. Oncogene 2020; 39(24): 4666-80.
[http://dx.doi.org/10.1038/s41388-020-1321-5] [PMID: 32398865]
[33]
Moller-Levet CS, Betts GNJ, Harris AL, Homer JJ, West CML, Miller CJ. Exon array analysis of head and neck cancers identifies a hypoxia related splice variant of LAMA3 associated with a poor prognosis. PLOS Comput Biol 2009; 5(11): e1000571.
[http://dx.doi.org/10.1371/journal.pcbi.1000571] [PMID: 19936049]
[34]
Jones L, Naidoo M, Machado LR, Anthony K. The Duchenne muscular dystrophy gene and cancer. Cell Oncol 2021; 44(1): 19-32.
[http://dx.doi.org/10.1007/s13402-020-00572-y] [PMID: 33188621]
[35]
Tan S, Tan J, Tan S, et al. Decreased Dp71 expression is associated with gastric adenocarcinoma prognosis. Oncotarget 2016; 7(33): 53702-11.
[http://dx.doi.org/10.18632/oncotarget.10724] [PMID: 27449096]
[36]
Zhou S, Ouyang W, Zhang X, et al. UTRN inhibits melanoma growth by suppressing p38 and JNK/c-Jun signaling pathways. Cancer Cell Int 2021; 21(1): 88.
[http://dx.doi.org/10.1186/s12935-021-01768-4] [PMID: 33632212]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy